ARHGAP44 is a Rho GTPase-activating protein that regulates cellular processes through its GAP activity on CDC42 and RAC1 1. The protein catalyzes GTP hydrolysis on CDC42, controlling the cycling between active GTP-bound and inactive GDP-bound states of Rho-type GTPases 1. ARHGAP44 functions as a tumor suppressor whose downregulation promotes cancer progression through multiple mechanisms. Mutant p53 suppresses ARHGAP44 transcription, leading to increased GTP-CDC42 levels and enhanced cell spreading and migration 1. In osteosarcoma, high ARHGAP44 expression correlates with metastasis and poor prognosis, with downregulation of ARHGAP44 inhibiting malignant behavior by modulating the p53/C-myc/Cyclin D1 pathway 23. The gene shows reduced expression in lung carcinoma compared to normal tissues, particularly in tumors harboring mutant p53 1. ARHGAP44 has been identified as a potential biomarker in colorectal cancer progression and is associated with immune infiltration 4. Recent studies suggest ARHGAP44 may influence glycemic homeostasis, as genetic variants in this locus are associated with longitudinal changes in hemoglobin A1c levels 5. These findings position ARHGAP44 as both a prognostic biomarker and potential therapeutic target across multiple cancer types.